PortalPublikationenRe-assessment of 30-, 60- and 90-day mortality rates in non-...

Re-assessment of 30-, 60- and 90-day mortality rates in non-metastatic prostate cancer patients treated either with radical prostatectomy or radiation therapy

Standard

Re-assessment of 30-, 60- and 90-day mortality rates in non-metastatic prostate cancer patients treated either with radical prostatectomy or radiation therapy. / Hansen, Jens; Gandaglia, Giorgio; Bianchi, Marco; Sun, Maxine; Rink, Michael; Tian, Zhe; Meskawi, Malek; Trinh, Quoc-Dien; Shariat, Shahrokh F; Perrotte, Paul; Chun, Felix K-H; Graefen, Markus; Karakiewicz, Pierre I.

in: CUAJ-CAN UROL ASSOC, Jahrgang 8, Nr. 1-2, 2014, S. E75-80.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Hansen, J, Gandaglia, G, Bianchi, M, Sun, M, Rink, M, Tian, Z, Meskawi, M, Trinh, Q-D, Shariat, SF, Perrotte, P, Chun, FK-H, Graefen, M & Karakiewicz, PI 2014, 'Re-assessment of 30-, 60- and 90-day mortality rates in non-metastatic prostate cancer patients treated either with radical prostatectomy or radiation therapy', CUAJ-CAN UROL ASSOC, Jg. 8, Nr. 1-2, S. E75-80. https://doi.org/10.5489/cuaj.749

APA

Hansen, J., Gandaglia, G., Bianchi, M., Sun, M., Rink, M., Tian, Z., Meskawi, M., Trinh, Q-D., Shariat, S. F., Perrotte, P., Chun, F. K-H., Graefen, M., & Karakiewicz, P. I. (2014). Re-assessment of 30-, 60- and 90-day mortality rates in non-metastatic prostate cancer patients treated either with radical prostatectomy or radiation therapy. CUAJ-CAN UROL ASSOC, 8(1-2), E75-80. https://doi.org/10.5489/cuaj.749

Vancouver

Hansen J, Gandaglia G, Bianchi M, Sun M, Rink M, Tian Z et al. Re-assessment of 30-, 60- and 90-day mortality rates in non-metastatic prostate cancer patients treated either with radical prostatectomy or radiation therapy. CUAJ-CAN UROL ASSOC. 2014;8(1-2):E75-80. https://doi.org/10.5489/cuaj.749

Bibtex

@article{89bd8fefaf4241f1b280fcf80303d663,
title = "Re-assessment of 30-, 60- and 90-day mortality rates in non-metastatic prostate cancer patients treated either with radical prostatectomy or radiation therapy",
abstract = "INTRODUCTION: It is customary to consider deaths that occur within 90 days of surgery as caused by that surgery. However, such practice may overestimate the true short-term mortality rates after radical prostatectomy (RP). Indeed, treatment-unrelated events might affect short-term mortality rates. We assess RP-specific excess short-term mortality.METHODS: We performed a retrospective analysis of a population-based cohort of 59 010 patients (RP = 28 281 and external beam radiation therapy [EBRT] as reference group, n = 30 729) who were treated between 1998 and 2005 for non-metastatic prostate cancer. Using univariate and multivariate logistic regression analyses, we assessed the rates of 30-, 60- and 90-day mortality after either RP or EBRT.RESULTS: Within the cohort, 30-, 60- and 90-day mortality rates were 0.2, 0.5 and 0.6%, and 0.1, 0.4 and 0.6% for RP and EBRT patients, respectively. This resulted in overall 30-, 60, and 90- day mortality differences of 0.1, 0.1 and 0%, respectively. After stratification according to age and Charlson comorbidity index (CCI), the magnitude of these differences increased up to 3.2% in favour of EBRT in patients aged >75 years with CCI ≥2. In multivariable analysis, rates of 30-, 60- and 90- day mortality were 5.2-, 1.8- and 1.3-fold higher after RP than EBRT, respectively. Our study is limited by its non-randomized design.CONCLUSION: Overall, absolute short-term mortality rates after RP are comparable to those of EBRT. The difference decreases over time: 90 days <60 days <30 days. Nonetheless, their magnitude is far from trivial in the elderly and sickest patients.",
author = "Jens Hansen and Giorgio Gandaglia and Marco Bianchi and Maxine Sun and Michael Rink and Zhe Tian and Malek Meskawi and Quoc-Dien Trinh and Shariat, {Shahrokh F} and Paul Perrotte and Chun, {Felix K-H} and Markus Graefen and Karakiewicz, {Pierre I}",
year = "2014",
doi = "10.5489/cuaj.749",
language = "English",
volume = "8",
pages = "E75--80",
journal = "CUAJ-CAN UROL ASSOC",
issn = "1911-6470",
publisher = "Canadian Medical Association",
number = "1-2",

}

RIS

TY - JOUR

T1 - Re-assessment of 30-, 60- and 90-day mortality rates in non-metastatic prostate cancer patients treated either with radical prostatectomy or radiation therapy

AU - Hansen, Jens

AU - Gandaglia, Giorgio

AU - Bianchi, Marco

AU - Sun, Maxine

AU - Rink, Michael

AU - Tian, Zhe

AU - Meskawi, Malek

AU - Trinh, Quoc-Dien

AU - Shariat, Shahrokh F

AU - Perrotte, Paul

AU - Chun, Felix K-H

AU - Graefen, Markus

AU - Karakiewicz, Pierre I

PY - 2014

Y1 - 2014

N2 - INTRODUCTION: It is customary to consider deaths that occur within 90 days of surgery as caused by that surgery. However, such practice may overestimate the true short-term mortality rates after radical prostatectomy (RP). Indeed, treatment-unrelated events might affect short-term mortality rates. We assess RP-specific excess short-term mortality.METHODS: We performed a retrospective analysis of a population-based cohort of 59 010 patients (RP = 28 281 and external beam radiation therapy [EBRT] as reference group, n = 30 729) who were treated between 1998 and 2005 for non-metastatic prostate cancer. Using univariate and multivariate logistic regression analyses, we assessed the rates of 30-, 60- and 90-day mortality after either RP or EBRT.RESULTS: Within the cohort, 30-, 60- and 90-day mortality rates were 0.2, 0.5 and 0.6%, and 0.1, 0.4 and 0.6% for RP and EBRT patients, respectively. This resulted in overall 30-, 60, and 90- day mortality differences of 0.1, 0.1 and 0%, respectively. After stratification according to age and Charlson comorbidity index (CCI), the magnitude of these differences increased up to 3.2% in favour of EBRT in patients aged >75 years with CCI ≥2. In multivariable analysis, rates of 30-, 60- and 90- day mortality were 5.2-, 1.8- and 1.3-fold higher after RP than EBRT, respectively. Our study is limited by its non-randomized design.CONCLUSION: Overall, absolute short-term mortality rates after RP are comparable to those of EBRT. The difference decreases over time: 90 days <60 days <30 days. Nonetheless, their magnitude is far from trivial in the elderly and sickest patients.

AB - INTRODUCTION: It is customary to consider deaths that occur within 90 days of surgery as caused by that surgery. However, such practice may overestimate the true short-term mortality rates after radical prostatectomy (RP). Indeed, treatment-unrelated events might affect short-term mortality rates. We assess RP-specific excess short-term mortality.METHODS: We performed a retrospective analysis of a population-based cohort of 59 010 patients (RP = 28 281 and external beam radiation therapy [EBRT] as reference group, n = 30 729) who were treated between 1998 and 2005 for non-metastatic prostate cancer. Using univariate and multivariate logistic regression analyses, we assessed the rates of 30-, 60- and 90-day mortality after either RP or EBRT.RESULTS: Within the cohort, 30-, 60- and 90-day mortality rates were 0.2, 0.5 and 0.6%, and 0.1, 0.4 and 0.6% for RP and EBRT patients, respectively. This resulted in overall 30-, 60, and 90- day mortality differences of 0.1, 0.1 and 0%, respectively. After stratification according to age and Charlson comorbidity index (CCI), the magnitude of these differences increased up to 3.2% in favour of EBRT in patients aged >75 years with CCI ≥2. In multivariable analysis, rates of 30-, 60- and 90- day mortality were 5.2-, 1.8- and 1.3-fold higher after RP than EBRT, respectively. Our study is limited by its non-randomized design.CONCLUSION: Overall, absolute short-term mortality rates after RP are comparable to those of EBRT. The difference decreases over time: 90 days <60 days <30 days. Nonetheless, their magnitude is far from trivial in the elderly and sickest patients.

U2 - 10.5489/cuaj.749

DO - 10.5489/cuaj.749

M3 - SCORING: Journal article

C2 - 24554978

VL - 8

SP - E75-80

JO - CUAJ-CAN UROL ASSOC

JF - CUAJ-CAN UROL ASSOC

SN - 1911-6470

IS - 1-2

ER -